Philip A. Dy

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Nitin Jain, Emily Curran, Neil M. Iyengar et al. · Clinical Cancer Research · 2013 · 111 citations · Full text

Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622

Anne F. Schott, William E. Barlow, Catherine Van Poznak et al. · Breast Cancer Research and Treatment · 2016 · 57 citations · Full text

Breast Oncology, Medicine, Cancer Management +8

Policies for Reintegrating Crop and Livestock Systems: A Comparative Analysis

Rachael Garrett, Meredith T. Niles, Juliana Gil et al. · Sustainability · 2017 · 56 citations · Full text

Land Use, Agricultural Economics, Environmental Economics +17

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Andrew M. Evens, Fangxin Hong, Thomas M. Habermann et al. · Clinical Cancer Research · 2020 · 22 citations · Full text

Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group

Priya Rastogi, Marc Buyse, Sandra M. Swain et al. · Clinical Breast Cancer · 2011 · 20 citations

Breast Oncology, Oncology, Concurrent Bevacizumab +8